Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

A psychedelic renaissance

Fifty-three years after LSD was banned by the FDA, psychedelic drugs are making a comeback. Only instead of being the pills, mushrooms and acid tabs that helped college students to “turn on, tune in, drop out” Timothy Leary-style, today’...
Richard (Rick) Mills | December 3, 2019 |

Horizon Therapeutics Shares Rise 15% on Strong Q1 Results and Raised F/Y Sales Guidance

Shares of Horizon Therapeutics traded higher setting a new 52-week high price after the company reported a 27% y-o-y increase in net sales for Q1/20 and raised FY/20 net sales guidance. Biopharmaceutical company Horizon Therapeutics Inc. (HZNP:NASDAQ) , whi...
Streetwise Reports | May 7, 2020 |

Energy Firm Posts Solid Q2, Positions Itself for Price Uncertainty

A Haywood report explains why TORC Oil & Gas is "well positioned to ride out the current tumultuous oil price environment." In a May 6 research note, Haywood analyst Christopher Jones reported that TORC Oil & Gas Ltd. (TOG:TSX) had a "sound" Q2 FY20 and made stra...
Streetwise Reports | May 15, 2020 |

“Little Red Book” App - Will It Destroy Democracy?

You are probably familiar with the most printed book in the world: the Bible. But you’ve probably never even heard of the second-most printed book. It’s known as the “Little Red Book,” or officially “Quotations from ...
Marin Katusa | March 8, 2019 |

Buzz on the Bullboards: Investors Talk Cannabis on “10/17”

In the United States, they have “420”. This pop culture reference was a numerical label for 4:20 pm – a time when (according to this urban legend) a group of California high school students would meet to smoke cannabis. But this is also a symbol of the e...
Stockhouse Editorial | October 18, 2018 |

Interview with Lukas Lundin

“One drill hole changes the game. It’s very hard to decide who gets to make it and who doesn’t. It’s a big gate, and yet very few make it through. But you have to let them try.” — Lukas Lundin ...
Tommy Humphreys | May 6, 2013 |

Biopharma Co. Makes Major Headway Toward Clinical Trials for Treatment of Stroke

(CLICK IMAGE TO PLAY VIDEO) Finding an effective method of preventing the possibility of stroke is something that medical science has grappled with for decades. Now, a Vancouver-based clinical stage biopharmaceutical development company looks to be making significa...
Dave Jackson | June 16, 2021 |

Two Fed Nominations Every Gold Investor Should Be Aware Of

The delicate balance of forces at the Fed has been disturbed. The doves grew stronger recently, and with new governors coming, their strength may increase even further. Will gold warm up to them? Goldbug in the Fed? Trump wants to nominate a goldbug to the Federal Res...
Arkadiusz Sieron | July 19, 2019 |

Soliton Shares Rise on Announcement It Will Report Clinical Data at National Dermatology Conference

Soliton Inc. shares traded 10% higher today after advising that later this month it will present the data from clinical trials for its Rapid Acoustic Pulse device used in the treatment of keloid and hypertrophic scars at the American Society for Dermatologic Surgery Annual Mee...
Streetwise Reports | October 10, 2019 |

Leap Therapeutics Lunges Forward on $132M Licensing Deal and $27M Equity Raise

Shares of Leap Therapeutics jumped 60% after the company reported that it signed an exclusive option and license agreement for its immuno-oncology drug DKN-01 with BeiGene in the Asia Pacific region excluding Japan. The firm also secured an additional $27 million in equity fin...
Streetwise Reports | January 6, 2020 |
1 2 3